To interrogate the role of CCL5 in HSC migration, TSC were pretreated with a CCR5 antagonist (Met‐CCL5, 100 ng/ml) before seeding and Met‐CCL5 was supplemented in the media of devices with TSC. Here, CCL5 is linked to tuberous sclerosis.